Phase 2/3 CARDINAL trial of bardoxolone methyl in patients with CKD caused by Alport syndrome

Reata is enrolling patients in the Phase 3 portion of its Phase 2/3 CARDINAL trial of bardoxolone methyl in patients with CKD caused by Alport syndrome. We expect data in the second half of 2019.